OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Before Annual Forum

June 25, 2026 4:13 AM

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $9.00 price target on OptimizeRX (NASDAQ: OPRX).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found